NeuroMetrix, Inc. Announces Date for First Quarter 2022 Financial Results Conference CallGlobeNewsWire • 04/19/22
NeuroMetrix Reports that Quell® Wearable Neuromodulator to be Evaluated in Post-Acute COVID-19 SyndromeGlobeNewsWire • 02/24/22
NeuroMetrix, Inc.'s (NURO) CEO Dr. Shai Gozani on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 01/27/22
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2021 Financial Results Conference CallGlobeNewsWire • 01/20/22
NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN) with its Wearable Neurostimulation TechnologyGlobeNewsWire • 01/18/22
NeuroMetrix Names Strategic Growth Executive, Brandi Damkier, as Vice President, Clinical PartnershipsGlobeNewsWire • 01/10/22
NeuroMetrix, Inc. (NURO) CEO Dr. Shai Gozani on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 10/21/21
NeuroMetrix Names Strategic Growth Executive, Susan M. Bell, RN, BN, as Senior Vice President of Population Health & Value Based CareGlobeNewsWire • 10/20/21
NeuroMetrix, Inc. Announces Date for Third Quarter 2021 Financial Results Conference CallGlobeNewsWire • 10/14/21
NeuroMetrix Announces Submission of FDA De Novo Request for Treatment of Fibromyalgia Symptoms with the Quell® Wearable Neuromodulation DeviceGlobeNewsWire • 10/06/21
NeuroMetrix Announces Participation in the Center to Stream Healthcare In Place (C2SHIP) as an Industry PartnerGlobeNewsWire • 10/05/21